News & Updates

Gabapentin may promote abstinence in alcohol use disorder

04 Oct 2021

A recent study shows evidence for a biomarker of efficacious treatment that may be used to assess other glutamatergic or GABAergic medications for alcohol use disorder (AUD) and related conditions, as well as provide insight into the means through which gabapentin may promote abstinence in individuals with AUD.

Gabapentin may promote abstinence in alcohol use disorder

04 Oct 2021

Varenicline plus naltrexone may aid in smoking cessation, drinking reduction

04 Oct 2021

Varenicline alone is an adequate therapy for smoking cessation in heavy-drinking smokers, but combining it with naltrexone may provide benefits in terms of drinking outcomes, particularly during the 12-week period of active medication treatment, suggests a study.

Varenicline plus naltrexone may aid in smoking cessation, drinking reduction

04 Oct 2021

Original New Drug Application Approvals by US FDA (16-30 September 2021)

04 Oct 2021

New drug applications approved by US FDA as of 16 -30 September 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2021)

04 Oct 2021

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

04 Oct 2021

Treatment with azathioprine helps prevent relapse of autoimmune pancreatitis, according to the results of a systematic review and meta-analysis.

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

04 Oct 2021

Mepolizumab add-on shrinks nasal polyp in CRSwNP

03 Oct 2021 by

Add-on treatment with the anti-IL-5 biologic mepolizumab significantly reduces nasal polyp size and nasal obstruction, along with less need for surgery and systemic corticosteroid use compared with standard care alone in patients with recurrent, refractory, and severe chronic rhinosinusitis with nasal polyps (CRSwNP), the SYNAPSE study shows.

Mepolizumab add-on shrinks nasal polyp in CRSwNP

03 Oct 2021

Dose escalation intolerance disrupts maintenance therapy of children with ALL

03 Oct 2021

Only a few children with acute lymphoblastic leukaemia (ALL) treated with mercaptopurine (6MP) and methotrexate (MTX) complete their maintenance therapy without interruptions at the current dose escalation schedules outlined by the Children’s Oncology Group protocols, a study has shown.

Dose escalation intolerance disrupts maintenance therapy of children with ALL

03 Oct 2021

Drug interactions in breast cancer therapy may harm patients

02 Oct 2021

Several drug-drug interactions (DDIs) found in breast cancer treatment may lead to adverse consequences on patient health and therapeutic outcomes, suggests a study.

Drug interactions in breast cancer therapy may harm patients

02 Oct 2021

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

02 Oct 2021

Tyrosine kinase inhibitors (TKIs) are a safe and effective first-line treatment for metastatic renal cell cancer (mRCC), confirms a Turkey study. In addition, no significant difference has been observed among three TKI agents (sunitinib, pazopanib, and sorafenib) in terms of treatment duration, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

02 Oct 2021

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

02 Oct 2021

Antiplatelet therapy guided by platelet function monitoring helps prevent thromboembolic events among patients with unruptured intracranial aneurysm who have undergone stent placement but at the cost of higher minor or minimal bleeding events, according to data from an open-label study.

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

02 Oct 2021

COVID-19 vacc side effects: Fewer than expected?

01 Oct 2021 by

A community-based study from the UK showed that the rate of systemic side effects is relatively low following vaccination with the BNT162b2 or ChAdOx1 nCoV-19 COVID-19 vaccines.

COVID-19 vacc side effects: Fewer than expected?

01 Oct 2021

News & Updates

Filter by Specialty:

Specialty:

Gabapentin may promote abstinence in alcohol use disorder

Gabapentin may promote abstinence in alcohol use disorder

Varenicline plus naltrexone may aid in smoking cessation, drinking reduction

Varenicline plus naltrexone may aid in smoking cessation, drinking reduction

Original New Drug Application Approvals by US FDA (16-30 September 2021)

Original New Drug Application Approvals by US FDA (16-30 September 2021)

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

Azathioprine shows promise in maintenance treatment of autoimmune pancreatitis

Mepolizumab add-on shrinks nasal polyp in CRSwNP

Mepolizumab add-on shrinks nasal polyp in CRSwNP

Dose escalation intolerance disrupts maintenance therapy of children with ALL

Dose escalation intolerance disrupts maintenance therapy of children with ALL

Drug interactions in breast cancer therapy may harm patients

Drug interactions in breast cancer therapy may harm patients

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

TKIs safe, effective as first-line therapy in cytokine-intolerant metastatic renal cell cancer

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

Adjusted antiplatelet therapy after stenting beneficial to unruptured intracranial aneurysm patients

COVID-19 vacc side effects: Fewer than expected?

COVID-19 vacc side effects: Fewer than expected?